Preclinical Drug Evaluation
Preclinical Drug Evaluation - Related Videos
09:19
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
0 Views •
Cited by 4 •
2015
Here, real-time monitoring of tumor cell metabolism, combined with an in vivo chicken embryo chorio-allantoic membrane (CAM) model of metastasis, are used to evaluate novel anti-cancer targets/agents for their ability to sensitize tumor cells to DNA damaging chemotherapeutics.
08:47
Experimental Quantification of Interactions Between Drug Delivery Systems and Cells In Vitro: A Guide for Preclinical Nanomedicine Evaluation
0 Views •
Cited by 2 •
2022
A workflow is demonstrated for the absolute quantification of drug carrier-cell interactions using flow cytometry to allow better rational evaluation of novel drug delivery systems. This workflow is applicable to drug carriers of any type.
03:40
β-Galactosidase Assay to Evaluate Drug-Induced Cytotoxicity in Parasites
0 Views •
2023
In this video, we describe a simple and robust method to determine the cytotoxic potential of a trypanocidal drug against a parasite, Trypanosoma cruzi, expressing the β-galactosidase enzyme. β-galactosidase serves as a cell lysis indicator, and its activity can be used to assess the effects of the drug.
08:07
Preclinical Drug Testing in Scalable 3D Engineered Muscle Tissues
0 Views •
Cited by 5 •
2023
This protocol provides methods for generating 3D engineered cardiac and skeletal muscle tissues and describes their use in preclinical drug screening modalities. The described methods utilize a magnetic sensing system to facilitate the simultaneous assessment of 24 tissues in parallel.
06:08
Evaluation of Drug Sorption to PVC- and Non-PVC-based Tubes in Administration Sets Using a Pump
0 Views •
Cited by 8 •
2017
We report a method for drug sorption evaluation using a pump and model drugs (diazepam and tacrolimus). After drug analysis using high-performance liquid chromatography, drug concentrations and sorption levels in the tubes of administration sets are calculated.
FAQs
Researchers examine whether a candidate compound can reach the nervous system by assessing its ability to cross the blood-brain barrier. This information helps determine whether biological activity observed outside the brain is likely to translate into effects within neural tissue. The result can influence candidate selection, interpretation of nervous-system responses, and planning of later dosing studies.
Pharmacokinetics describes how a compound is handled over time, including its metabolism, while dose-response analysis links exposure to biological or therapeutic effects. Evaluating both helps researchers identify doses associated with desired activity and recognize levels that may produce toxicity. These findings support rational dosing strategies and clarify how strongly a candidate affects disease-relevant pathways.
Each model provides a different level of evidence. Cell-based assays can reveal biological activity, molecular studies can examine effects on disease-relevant pathways, and animal models can connect treatment exposure with behavioral or physiological outcomes. Considering these results together helps researchers judge whether a candidate produces consistent effects across systems rather than relying on a single experimental perspective.
A typical workflow combines biological testing with studies of nervous-system access, pharmacokinetics, dose response, metabolism, and toxicity. Researchers then examine behavioral or physiological outcomes in appropriate experimental models and compare the findings across study types. This sequence helps identify promising candidates, refine dosing strategies, and determine which questions require further investigation before human trials.
The studies can show whether a compound has biological activity, reaches relevant nervous-system tissues, alters disease-related pathways, and produces measurable behavioral or physiological effects. They also reveal how the candidate is metabolized and whether toxicity emerges at tested doses. Together, these outcomes provide evidence for therapeutic potential while identifying limitations that may affect later development.
Findings from these studies help determine which candidates warrant further development and how future studies should be designed. Evidence about nervous-system access, dose response, metabolism, toxicity, and disease-relevant effects can shape dosing strategies and selection of experimental endpoints. In neuroscience, this process is especially important because a compound must produce relevant effects within the nervous system to support its proposed therapeutic use.